Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice

Physiology and Behavior

Volumn 80, Issue 4, 2004, Pages 415-420

  Lalonde, Josée ^a   Samson, Pierre ^a   Poulin, Sébastien ^a   Deshaies, Yves ^a   Richard, Denis ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Antiepilepsy drugs; Body composition; Body weight; Food intake; Glucose; Insulin; Obesity

Indexed keywords

ANTICONVULSIVE AGENT; BUFFER; FAT; GLUCOSE; GLUCOSE OXIDASE; INSULIN; LEPTIN; PHOSPHATE; SODIUM CHLORIDE; TOPIRAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG POTENTIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY BALANCE; FEMALE; FOOD INTAKE; GLUCOSE ASSAY; HORMONE DETERMINATION; HYPERINSULINEMIA; LEAN BODY WEIGHT; LIPID STORAGE; NONHUMAN; OBESITY; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RADIOIMMUNOASSAY; STATISTICAL SIGNIFICANCE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 1642565342     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2003.08.013     Document Type: Article

References (44)

1. Von Seggern R.L., Mannix L.K., Adelman J.U. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache. 42:2002;804-809.
2. Vieta E., Torrent C., Garcia-Ribas G., Gilabert A., Garcia-Pares G., Rodriguez A.et al. Use of topiramate in treatment-resistant bipolar spectrum disorders. J. Clin. Psychopharmacol. 22:2002;431-435.
3. Maidment I.D. The use of topiramate in mood stabilization. Ann. Pharmacother. 36:2002;1277-1281.
4. Appolinario J.C., Fontenelle L.F., Papelbaum M., Bueno J.R., Coutinho W. Topiramate use in obese patients with binge eating disorder: an open study. Can. J. Psychiatry. 47:2002;271-273.
5. White H.S., Brown S.D., Woodhead J.H., Skeen G.A., Wolf H.H. Topiramate enhances GABA-mediated chloride flux and GABA-evoked currents in mouse brain neurons and increases seizure threshold. Epilepsy Res. 28:1997;167-179.
6. White H.S., Skeen G.A., Woodhead J., Wolf H.H. Topiramate modulates GABA-evoked currents in murine cortical neurons by non-benzodiazepine mechanism. Epilepsia. 41:2000;S17-S20.
7. Gibbs J.W., Sombati S., DeLorenzo R.J., Coulter D.A. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 41:2000;S10-S16.
8. Skradski S., White H.S. The novel antiepileptic drug topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 41:2000;S45-S47.
9. + current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. 288:2000;960-968.
10. Zona C., Ciotti M.T., Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells in culture. Neurosci. Lett. 231:1997;123-126.
11. DeLorenzo R.J., Sombati S., Coulter D.A. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia. 41:2000;S40-S44.
12. Wu S.P., Tsai J.J., Gean P.W. Frequency-dependent inhibition of neuronal firing by topiramate in hippocampal slices. Br. J. Pharmacol. 125:1999;826-832.
13. McLean M.J., Bukhari A.A., Wamil A.W. Effects of topiramate on sodium-dependent action potential firing by mouse spinal cord neurons in cell culture. Epilepsia. 41:2000;S21-S24.
14. Zhang X.L., Velumian A., Jones O.T., Carlen P.L. Modulation of high voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 41:2000;S52-S60.
15. Dodgson S.J., Shank R.P., Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isozymes. Epilepsia. 41:2000;S35-S39.
16. Herrero A.I., DelOlmo N., GonzalezEscalada J.R., Solis J.M. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology. 42:2002;210-220.
17. Brown R.O., Orr C.D., Hanna D.L., Williams J.E., Dickerson R.N. Topiramate and weight loss in patients with neurodevelopmental disabilities. Pharmacotherapy. 22:2002;831-835.
18. Roy Chengappa K.N., Levine J., Rathore D., Parepally H., Atzert R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series. Eur. Psychiatry. 16:2001;186-190.
19. Carpenter L.L., Leon Z., Yasmin S., Price L.H. Do obese depressed patients respond to topiramate? A retrospective chart review. J. Affect. Disord. 69:2002;251-255.
20. Schuler-Springorum M., Hebebrand J., Wehmeier P.M., Remschmidt H. Is topiramate effective for weight loss in neuroleptic-induced obesity? 2 Case reports. Z. Kinder. Jugendpsychiatr. Psychother. 30:2002;51-58.
21. Teter C.J., Early J.J., Gibbs C.M. Treatment of affective disorder and obesity with topiramate. Ann. Pharmacother. 34:2000;1262-1265.
22. York D.A., Singer L., Thomas S., Bray G.A. Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition. 16:2000;967-975.
23. Picard F., Deshaies Y., Lalonde J., Samson P., Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes. Res. 8:2000;656-663.
24. Richard D., Ferland J., Lalonde J., Samson P., Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition. 16:2000;961-966.
25. Richard D., Picard F., Lemieux C., Lalonde J., Samson P., Deshaies Y. Effects of topiramate and sex hormones on energy balance of male and female rats. Int. J. Obes. 26:2002;344-353.
26. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature. 395:1998;763-770.
27. Halaas J.L., Gajiwala K.S., Maffei M., Cohen S.L., Chait B., Rabinowitz D.et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 269:1995;543-546.
28. Campfield L.A., Smith F.J., Guisez Y., Devos R., Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 269:1995;546-549.
29. Pelleymounter M.A., Cullen M.J., Baker M.B., Hecht R., Winters D., Boone T.et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 269:1995;540-543.
30. York D.A. The characteristics of genetically obese mutants. Festing M.F.W. The characteristics of genetically obese mutants. 1979;39-64 MacMillan, New York.
31. McGinnis R., Walker J., Margules D., Aird F., Redei E. Dysregulation of the hypothalamus-pituitary-adrenal axis in male and female, genetically obese (ob/ob) mice. J. Neuroendocrinol. 4:1992;765-771.
32. Nagy T.R., Clair A.L. Precision and accuracy of dual-energy X-ray absorptiometry for determining in vivo body composition of mice. Obes. Res. 8:2000;392-398.
33. Seufert J., Kieffer T.J., Habener J.F. Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;674-679.
34. Scarpace P.J., Matheny M., Pollock B.H., Tumer N. Leptin increases uncoupling protein expression and energy expenditure. Am. J. Physiol. 273:1997;E226-E230.
35. Schwartz M., Seeley R.J., Campfield L.A., Burn P., Baskin D.G. Identification of targets of leptin action in rat hypothalamus. J. Clin. Invest. 98:1996;1101-1106.
36. Baskin D.G., Schwartz M.W., Seeley R.J., Woods S.C., Porte D., Breininger J.F.et al. Leptin receptor long-form splice-variant protein expression in neuron cell bodies of the brain and co-localization with neuropeptide Y mRNA in the arcuate nucleus. J. Histochem. Cytochem. 47:1999;353-362.
37. Schwartz M.W., Seeley R.J., Woods S.C., Weigle D.S., Campfield L.A., Burn P.et al. Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus. Diabetes. 46:1997;2119-2123.
38. Schwartz M.W., Seeley R.J., Campfield L.A., Burn P., Baskin D.G. Identification of targets of leptin action in rat hypothalamus. J. Clin. Invest. 98:1996;1101-1106.
39. Mizuno T.M., Mobbs C.V. Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting. Endocrinology. 140:1999;814-817.
40. Nowak K.W., Pierzchala-Koziec K., Tortorella C., Nussdorfer G.G., Malendowicz L.K. Effects of prolonged leptin infusion on rat pituitary-adrenocortical function. Int. J. Mol. Med. 9:2002;61-64.
41. Giovambattista A., Chisari A.N., Gaillard R.C., Spinedi E. Food intake-induced leptin secretion modulates hypothalamo-pituitary-adrenal axis response and hypothalamic Ob-Rb expression to insulin administration. Neuroendocrinology. 72:2000;341-349.
42. Gordon A., Price L.H. Mood stabilization and weight loss with topiramate. [letter] Am. J. Psychiatry. 156:1999;968-969.
43. Ketter T.A., Post R.M., Theodore W.H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. [In Process Citation] Neurology. 53:1999;S53-S67.
44. Baulac M., Arzimanoglou A., Semah F., Cavalcanti D. Therapeutic options provided by new antiepileptic drugs. Rev. Neurol. (Paris). 155:1997;21-33.